agenus inc (AGEN:NASDAQ CM)
Transactions by AGENUS INC (AGEN) in the last 6 months
Agenus Inc. (NasdaqCM:AGEN) announced that it will receive $2,142,000 in funding on September 8, 2015. The company will issue common stock in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Agenus Inc. (NasdaqCM:AGEN) and its wholly-owned subsidiaries, Antigenics LLC and Aronex Pharmaceuticals, Inc. announced that it has entered into a note purchase agreement for a private placement of 13.5% limited recourse notes for gross proceeds of $100,000,000 on September 4, 2015. The transaction was led by new lender Oberland Capital Management LLC and other investors. The company has the option to issue an additional $15,000,000 aggregate principal amount of notes ...
Agenus Inc. (NasdaqCM:AGEN) acquired rights of Carcinoembryonic Antigen Cell Adhesion Molecule 1 from DIATHEVA s.r.l. for $44 million on July 20, 2015. Under the terms of the agreement, the consideration involves certain upfront, early development, clinical trial and regulatory milestone payments for the successful development of CEACAM1 antibodies totaling as much as $44 million. Diatheva is also eligible to receive additional sales milestones and royalties. Brad Miles ...
|No competitor information is available for AGEN.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|